Vulvar and Vaginal Atrophy Therapy Market Share

North American Market Forecast   

North America industry is poised to hold largest revenue share by 2037. The growth of the market can be attributed majorly to the surge in the number of women suffering from pre and postmenopausal hormonal imbalances along with the growing number of vaginal cancer cases in the region. For instance, according to the Centers for Disease Control and Prevention, in 2019, around 5,579 women (2.6 per 100,000) were diagnosed with vulvar cancer in the United States. Additionally, the boom in the instance of urinary tract infection cases in women owing to hypersexuality and unhealthy lifestyle and growing awareness of the infection is further anticipated to expand the regional market size during the forecast period. For instance, in 2022, it was estimated that around 45% of the women living in the USA are prone to get UTIs. Meanwhile, the doctor visits owing to UTIs are observed to be approximately 8 million every year.

APAC Market Statistics

The Asia Pacific vulvar and vaginal atrophy (VVA) therapy market, amongst the market in all the other regions, is projected to hold the second largest share during the forecast period. The growth of the market can be attributed majorly to the growing awareness of vulvar and vaginal atrophy basked by the escalating provision of required medication and the boom in the number of female geriatrics in the region. For instance, it was projected that in 2020, there were nearly 50% of geriatric females in the Asia Pacific. Women above 60 or 65 are considered to be geriatrics and highly prone to vaginal infection on account of the lack of estrogen. On the other hand, the increasing prevalence of UTI and vaginal cancers has also led to a higher demand for VVA therapy which results in a major growth driver to boost the market growth over the forecast period.